Investigate the Effect of AZD1305 on Patients With Left Ventricular Dysfunction

AstraZeneca

Status and phase: Completed; Phase 2

Conditions: Left Ventricle Function

Treatments: Drug: Placebo; Drug: AZD1305

Study type: Interventional

Funder types: Industry

Identifiers

NCT00748982

D3190C00013

2008-001254-41

Details and patient eligibility

About

To explore if AZD1305 compromises left ventricular performance in patients with left ventricular dysfunction

Enrollment: 16 patients

Sex: All

Ages: 20 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male patients and postmenopausal women
• Mildly/moderately decreased heart function
• Regular heart rhythm

Exclusion criteria

• Potassium outside normal reference values
• Child bearing potential
• Severely decreased heart function

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

16 participants in 2 patient groups, including a placebo group

1

Experimental group

Treatment:

Drug: AZD1305

2

Placebo Comparator group

Treatment:

Drug: Placebo